Diagnostics involves investigating and discovering certain diseases, conditions and injuries by closely studying various symptoms and indications displayed by patients. In broad terms, today’s Diagnostics Industry breaks down into the following categories, namely in-vitro diagnostics (IVD) (examination of diverse tissue samples in a laboratory) and in-vivo diagnostics (observation and testing of tissue and any organ’s functioning by exploiting the techniques like medical (diagnostic) imaging and monitoring).
A nearly EUR 37.5 billion sector, in-vitro diagnostics promises enormous growth potential, with governments increasingly redefining soaring healthcare spending and starting to pour investments into the high tech diagnostics business. The latter continues to be superintended by a mere scattering of behemoths. Major forces fuelling the industry development include, among others, innovative approaches regarding equipment and clinical trial activities.
This Catalogue presents an invaluable collection of research reports examining the Diagnostics and Diseases Market worldwide, by various regions and selected countries. The research reports feature market sizing analyses and growth rate reviews, discussions of factors diving or deterring the growth of the Diagnostics and Diseases Industry, information on market dynamics and share, etc. The profiles of large-to-micro caps, and the Diagnostics and Diseases Market forecasts are provided in the research reports too.
Publications found:
43,378
Sort by:
Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample(Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) - Global Forecast to 2028
US$ 4,950.00
... diagnostics market in 2013, followed by Asia-Pacific. A number of factors such as increase in waiver of CLIA for certain point of care diagnostic ...
March 2024
314 pages
Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
US$ 3,550.00
The Asia Pacific breast cancer therapeutics market was valued at US$ 6,986.37 million in 2022 and is expected to reach US$ 15,819.83 million by 2030; it is estimated to grow at a CAGR of 10.8% from 20...
March 2024
106 pages
2024 Coagulation Testing Market Shares in 16 Countries--Competitive Analysis of Leading and Emerging Market Players
US$ 2,500.00
This new report provides coagulation testing market shares for the following countries: China, Egypt, France, Germany, India, Italy, Japan, Philippines, Russia, Saudi Arabia, South Korea, Spain, Thail...
March 2024
2024 Europe Hemostasis Analyzers and Reagents--France, Germany, Italy, Spain, UK--Chromogenic, Immunodiagnostic, Molecular Coagulation Test Volume and Sales Segment Forecasts for Hospitals, Commercial/Private Labs and POC Locations--2023 Competitive Shares and Growth Strategies, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
US$ 14,500.00
This comprehensive five%li%country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the European coagulation testing...
March 2024
